Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
IsraelEnrolling By InvitationPHASE2, PHASE3
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Conditions
Generalized Myasthenia Gravis · gMG
Locations
- Ann and Robert H Lurie Children's Hospital of Chicago - Main Hospital, Chicago, Illinois, United States
- Atrium Health Neurology Specialty Care, Charlotte, North Carolina, United States
- University of Virginia (UVA) Health - Developmental Pediatrics Clinic, Charlottesville, Virginia, United States
- Universitair Ziekenhuis Antwerpen, Edegem, Belgium
- UZ Gent, Ghent, Belgium
- Childrens Hospital of Eastern Ontario, Ottawa, Canada
- AP-HM- Hôpital de La Timone, Marseille, France
- Universitätsklinikum Essen, Essen, Germany
- Hadassah Medical Center- Ein Kerem, Jerusalem, Israel
- Leids Universitair Medisch Centrum, Leiden, Netherlands
- Uniwersyteckie Centrum Kliniczne w Gdansku, Gdansk, Poland
- Wielospecjalistyczna Poradnia Lekarska Synapsis, Katowice, Poland
- Centralny Szpital Kliniczny - Uniwersyteckie Centrum Kliniczne WUM, Warsaw, Poland
- Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain
- Great Ormand Street Hospital for Children NHS Foundation Trust - Great Ormond Street Hospital - Pediatric Neurology, London, United Kingdom
- Oxford University Hospitals NHS Foundation Trust - John Radcliffe Hospital Children's Hospital, Oxford, United Kingdom